Swallow a camera pill to diagnose Crohn's? trial puts it to the test
NCT ID NCT06882993
First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time
Summary
Researchers are testing whether a camera pill that travels through the whole bowel can diagnose Crohn's disease without the need for colonoscopy and a separate small bowel exam. The trial enrolls people aged 18 to 40 who have symptoms and lab signs suggesting Crohn's disease. Participants receive either the camera pill or the standard combination of colonoscopy plus MRI or a small-bowel camera pill, and researchers track whether a complete diagnosis is reached without extra tests.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- pan-enteric capsule endoscopy, a camera pill that photographs the whole bowel
- What this could lead to
- If it works, people with suspected Crohn's disease could get a diagnosis from swallowing a camera pill instead of having a colonoscopy and an MRI or second capsule test.
- What could go wrong
- The camera pill may miss inflammation that colonoscopy or MRI would catch, and some patients may still need standard tests to confirm a diagnosis. The trial is small and early, so it cannot yet show whether the approach is as reliable as standard testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 165 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Clinical suspicion of CD\* * Age 18-40 years * Signed informed consent \*A clinical suspicion of CD is based on the following definition: * Diarrhea and/or abdominal pain for more than 1 month (or repeated episodes of diarrhea and/or abdominal pain) and either * fecal calprotectin ≥ 200 mg/kg or * fecal calprotectin ≥ 50 mg/kg plus one or more of the following findings: * C-reactive protein (CRP) \> 5 mg/L * Thrombocytosis (\> 400 x 109/L) * Anemia (hemoglobin \< 7.0 mmol/L for women and \< 8.0 mmol/L for men or a decrease \> 0.5 mmol/L compared to the usual level) * Prolonged fever (\> 37.5 ◦C for more than 2 weeks) * Weight loss (≥ 3 kg or ≥ 5% compared to the normal body weight) * Perianal abscess / fistula * Family history of inflammatory bowel disease. Exclusion Criteria: * Previous intestinal resection * Positive serologic markers for celiac disease * Positive stool polymerase chain reaction for pathogenic bacteria * Positive stool polymerase chain reaction for intestinal parasites * Suspected or established acute bowel obstruction (ileus) * Intake of NSAIDs or acetylsalicylic acid ≤ 4 weeks before inclusion, except low-dose, prophylactic acetylsalicylic acid (≤ 150 mg per day) * Intake of opioid or opioid-like medications ≤ 1 week before inclusion * Pregnancy or lactation * Inability to comply with protocol requirements, e.g. for reasons including alcohol or recreational drug abuse * Known gastrointestinal disorder other than functional gastrointestinal disorders * Renal failure defined by a plasma-creatinine above the normal reference range
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohn's disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Esbjerg Hospital - University Hospital of Southern Denmark
RECRUITINGEsbjerg, 6700, Denmark
-
Lillebaelt Hospital Vejle - University Hospital of Southern Denmark
RECRUITINGVejle, 7100, Denmark
-
Odense University Hospital
RECRUITINGOdense C, 5000, Denmark
-
Odense University Hospital - Svendborg Hospital
RECRUITINGSvendborg, 5700, Denmark
-
Skåne University Hospital
RECRUITINGMalmö, 205 02, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lab-Grown gut patches made from Patients' own cells tested against Crohn's ulcers
- Staph bacteria may hold clues to painful skin rashes in IBD patients on Anti-TNF therapy
- Can a drug plus surgery heal Crohn's fistulas for good?
- Do vegan yogurts and meat substitutes really boost your gut?
- AI reads scans to forecast Crohn's complications
- Can stem cell vesicles heal Crohn's fistulas?